Different effects of nabilone and cannabidiol on binocular depth inversion in man

Pharmacology Biochemistry and Behavior

Volumn 66, Issue 1, 2000, Pages 175-181

  Leweke, F Markus ^a   Schneider, Udo ^a   Radwan, Maren ^a   Schmidt, Eike ^a   Emrich, Hinderk M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Binocular depth inversion; Cannabidiol; Cannabinoids; Humans; Nabilone

Indexed keywords

CANNABIDIOL; NABILONE;

ADULT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOBIOLOGY; SCHIZOPHRENIA; SCORING SYSTEM; VISUAL ILLUSION;

ADULT; AFFECT; ANTI-ANXIETY AGENTS; CANNABIDIOL; DEPTH PERCEPTION; HUMANS; MALE; TETRAHYDROCANNABINOL;

CANNABIS;

EID: 0034080911     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00201-X     Document Type: Article

References (50)

1. Crick F., Koch C. The problem of consciousness. Sci. Am. 267:1992;150-152.
2. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 21:1980;175-185.
3. Dalton W.S., Martz R., Lemberger L, Rodda B.E., Forney R.B. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin. Pharmacol. Ther. 19:1976;300-309.
4. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
5. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
6. Emrich H.M. A three-component-system hypothesis of psychosis. Impairment of binocular depth inversion as an indicator of a functional dysequilibrium. Br. J. Psychiatry. 155:1989;S37-S39.
7. Emrich H.M., Leweke F.M., Schneider U. Towards a cannabinoid hypothesis of schizophrenia. Cognitive impairments due to a dysregulation of the endogenous cannabinoid system Pharmacol. Biochem. Behav. 56:1997;803-807.
8. Emrich H.M., Weber M.M., Wendl A., Zihl J., Meyer L.v., Hanisch W. Reduced binocular depth inversion as an indicator of cannabis-induced censorship impairment. Pharmacol. Biochem. Behav. 40:1991;S689-S690.
9. Fabre L.F., McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J. Clin. Pharmacol. 21:1981;377S-382S.
10. Frith C., Done D.J. Experiences of alien control in schizophrenia reflect a disorder to the central monitoring of action. Psychol. Med. 19:1989;356-363.
11. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
12. Gray J.A., Rawlins J.N.P. Comparator and buffer memory. An attempt to integrate two models of hippocampal functions Isaacson R.L., Pribham K.H. The hippocampus, vol. 4. 1986;159-201 Plenum Press, New York.
13. Gregory R.L. Eye and brain. The psychology of seeing. 1998;Oxford University Press, Oxford.
14. Haxby J.V., Horwitz B., Ungerleider L.V., Maisog J.M., Pietrini P., Grady C.L. The functional organization of human extrastriate cortex. APET-rCBF study of selective attention to faces and locations J. Neurosci. 14:1994;6336-6353.
15. Herkenham M, Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
16. Hill H., Bruce V. Independent effects of lighting, orientation, and stereopsis on the hollow-face illusion. Perception. 22:1993;887-897.
17. Hill H., Bruce V. A Comparison between the hollow-face and 'hollow-potato' illusions. Perception. 23:1994;1335-1337.
18. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
19. Hollister L.E., Gillespie H. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clin. Pharmacol. Ther. 18:1975;80-83.
20. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
21. Hunt C.A., Jones R.T., Herning R.I., Bachman J. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J. Pharmacokinet. Biopharmacol. 9:1981;245-260.
22. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 28:1974;172-177.
23. Lemberger L., Rowe H. Clinical pharmacology of nabilone, a cannabinol derivative. Clin. Pharmacol. Ther. 18:1975;720-726.
24. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 10:1999;1665-1669.
25. 9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berlin). 142:1999;230-235.
26. Malenka R.C., Angel R.W., Hampton B, Berger P.A. Impaired central error-correcting behavior in schizophrenia. Arch. Gen. Psychiatry. 39:1982;101-107.
27. Miller L.L., McFarland D.J., Cornett T.L., Brightwell D.R., Wikler A. Marijuana. Effects on free recall and subjective organization of pictures and words Psychopharmacology (Berlin). 55:1977;257-262.
28. Nakano S., Gillespie H.K., Hollister L.E. A model for evaluation of antianxiety drugs with the use of experimentally induced stress. Comparison of nabilone and diazepam Clin. Pharmacol. Ther. 23:1978;54-62.
29. Parker A.J., Cumming B.G., Johnston E.B., Hurlbert A.C. Multiple cues for three-dimensional shape. Gazzaniga M.S. The cognitive neurosciences. 1995;351-364 A Bradford Book, The MIT press, Cambridge, MA.
30. Petitet F., Jeantaud B., Reibaud M., Imperato A., Dubroeucq M.-C. Complex pharmacology of natural cannabinoids. Evidence for partial agonist activity of delta-8-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors Life Sci. 63:1998;PL1-PL6.
31. Poncelet M, Barnouin M.-C., Breliere J.-C., Le Fur G, Soubrie P. Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berlin). 144:1999;144-150.
32. Ramachandran V.S. Perception of shape from shading. Nature. 331:1988;163-166.
33. Richardson J.T.E. Mental imagery and Human memory. 1980;Macmillan, London; Basingstoke.
34. Rubin A., Lemberger L., Warrick P., Crabtree R.E., Sullivan H., Rowe H., Obermeyer B.D. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin. Pharmacol. Ther. 22:1977;85-91.
35. Schneider U., Leweke F.M., Niemczyk W., Sternemann U., Bevilacqua C.M., Emrich H.M. Impaired binocular depth inversion in patients with alcohol withdrawal. J. Psychiatr. Res. 30:1996;469-474.
36. Schneider U., Leweke F.M., Sternemann U., Weber M.M., Emrich H.M. Visual 3D illusion. A systems - Theoretical approach to psychosis Eur. Arch. Psychiatr. Clin. Neurosci. 246:1996;256-260.
37. Sheehan P.W. A shortened form of Bett's questionnaire upon mental imagery. J. Clin. Psychol. 23:1967;386-389.
38. Spielberger C.D., Gorsuch R.L., Lushene R.E. STAI, manual for the state-trait-anxiety-inventory. 1970;Consulting Psychologist Press, Palo Alto.
39. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates young-term potentiation. Nature. 388:1997;773-778.
40. van den Enden A., Spekreijse H. Binocular depth reversals despite familiarity cues. Science. 244:1989;959-961.
41. Ward A., Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs. 30:1985;127-144.
42. Wheatstone C. Contributions to the physiology of vision. l. On some remarkable, and hitherto unobserved, phenomena of binocular vision Philos. Trans. R. Soc. Lond. 128:1838;371-394.
43. Wheatstone C. Contributions to the physiology of vision. ll. On some remarkable, and hitherto unobserved, phenomena of binocular vision (continued) Philos. Trans. R. Soc. Lond. 142:1852;1-17.
44. White K., Sheehan P.W., Ashton R. Imagery assessment. A survey of self-report measures J. Mental Imagery. 1:1977;145-169.
45. Yellott J.I. Jr. Binocular depth inversion. Sci. Am. 245:1981;118-125.
46. Zerssen, D. v.: Die Befindlichkeits-Skala. In: Klinische Selbstbeurteilungs-Skalen (KSb-S) aus dem Müchner Psychiatrischen Informations-System (PSYCHIS München). Weinheim: Beltz Verlag; 1976.
47. Zuardi A.W., Morais S.L., Guimaraes F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry. 56:1995;485-486.
48. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berlin). 104:1991;260-264.
49. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berlin). 76:1982;245-250.
50. Zung W.W.K. A rating instrument for anxiety disorders. Psychosomatics. 12:1971;371-379.